Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0662-0419 in overweight or obesity
NCT06737536Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0662-0419 in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at 6 weeks. Started Dec 2024; status: completed.
02
Drugs
NNC0662-0419
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06737536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737536.